Results 1 to 10 of about 265 (112)

Zilebesiran: an RNA interference agent—its need and potential to transform hypertension treatment [PDF]

The Egyptian Heart Journal
Background Hypertension remains the leading modifiable risk factor for cardiovascular morbidity and mortality worldwide, yet nearly half of patients fail to achieve target blood pressure (BP) despite the availability of multiple antihypertensive agents ...
Sajeet Verma, Akshyaya Pradhan, Prashant Thandi   +2 more
doaj   +5 more sources

Zilebesiran—Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension [PDF]

Journal of Clinical Medicine
The inhibition of renin–angiotensin–aldosterone system (RAAS) activity is one of the key mechanisms in the treatment of arterial hypertension. Non-adherence to therapeutic recommendations is considered to be the main cause of failure to achieve therapeutic goals in patients with arterial hypertension.
Sylwia Dudzicz-Gojowy
exaly   +7 more sources

Zilebesiran as an Innovative siRNA-Based Therapeutic Approach for Hypertension: Emerging Perspectives in Cardiovascular Medicine [PDF]

International Journal of Molecular Sciences
Zilebesiran represents an innovative antihypertensive therapy employing small interfering RNA (siRNA) to inhibit hepatic angiotensinogen, a key regulator of the renin–angiotensin–aldosterone system. By directly targeting the source of angiotensin II production, zilebesiran offers a novel mechanism distinct from conventional antihypertensive treatments.
Morosan PA, Bobu AM, Carauleanu A, Popa R, Costea CF, Filip C, Buzduga CM, Patrascanu E, Cucu AI, Tudosa RI, Covali R, Haisan A.   +11 more
exaly   +5 more sources

Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations [PDF]

Life
Hypertension remains a major global health burden, and control rates remain suboptimal because of poor medication adherence and limitations of existing therapies, including escape within the renin–angiotensin–aldosterone system.
Jawaria, Areeba Noor, Yusra Zarlashat, Muhammad Ebad Asif Khan, Enrique Mandado Loureiro, Edit Dósa   +5 more
doaj   +3 more sources

Zilebesiran for treating hypertension; the result of recent findings [PDF]

Journal of Nephropathology
Given the pressing need for new medications with minimal adverse effects to address uncontrolled hypertension, this manuscript explores the potential of Zilebesiran as a crucial therapeutic agent. Zilebesiran is an experimental RNA interference drug that
Atefeh Saljoughian Esfahani, Yasaman Vahdani, Payam Peymani, Soha Razmjouei, Mahdieh Ahmadnia, Hadi Taghavinejad, Jyoti Baharani, Maryam Bakhshi   +7 more
doaj   +4 more sources

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension [PDF]

New England Journal of Medicine, 2023
Angiotensinogen is the sole precursor of angiotensin peptides and has a key role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis.In this phase 1 study, patients with hypertension were randomly assigned in a 2:1 ratio ...
George Bakris, Marianne T Sweetser, Don Foster   +2 more
exaly   +4 more sources

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.

JAMA
ImportanceIn prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months.ObjectiveTo evaluate the efficacy and safety of zilebesiran vs placebo when added to a standard ...
Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, Park W, Stiglitz D, Makarova N, Havasi A, Zappe DH, Saxena M, KARDIA-2 Study Group.   +12 more
europepmc   +5 more sources

Zilebesiran and Hypertension: A Systematic Review and Meta-analysis [PDF]

Journal of the Saudi Heart Association
Abstract: Objectives: Zilebesiran is an investigational RNA interference therapeutic designed to lower blood pressure by targeting the hepatic production of angiotensinogen, the most upstream precursor of the renin–angiotensin–aldosterone system. This approach aims to offer long-lasting blood pressure control with potentially fewer doses compared to ...
Lemine M, Almuzainy S, Aljubeh R, Alilo A.   +3 more
exaly   +4 more sources

Advancing hypertension management: the role of zilebesiran as an siRNA therapeutic agent [PDF]

Annals of Medicine and Surgery
Elevated blood pressure poses a significant global health challenge, affecting over 1.28 billion adults worldwide, with a staggering 46% unaware of their condition. Despite its pervasive impact and association with cardiovascular disease, hypertension remains inadequately controlled, highlighting the urgent need for innovative treatment approaches ...
Hala Najeeb, Abdul Moeed
exaly   +4 more sources

Novel Antihypertensive Medications to Target the Renin-Angiotensin System: Mechanisms and Research [PDF]

Reviews in Cardiovascular Medicine
An estimated 1.28 billion individuals in the global population suffer from hypertension. Importantly, uncontrolled hypertension is strongly linked to various cardiovascular and cerebrovascular diseases.
Zhe Jiang, Changlin Zhai, Guanmin Tang
doaj   +2 more sources